Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given an average recommendation of “Moderate Buy” by the eight analysts that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $55.38.

A number of research analysts have weighed in on CLDX shares. UBS Group began coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $44.00 target price on the stock. The Goldman Sachs Group reduced their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $19.95 on Thursday. The stock has a 50 day moving average price of $22.44 and a 200 day moving average price of $27.45. Celldex Therapeutics has a one year low of $18.61 and a one year high of $47.00. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -7.76 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, analysts predict that Celldex Therapeutics will post -2.48 earnings per share for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC increased its holdings in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 878 shares during the last quarter. KBC Group NV grew its stake in shares of Celldex Therapeutics by 31.2% in the third quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 495 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Celldex Therapeutics in the 4th quarter valued at $81,000. AlphaQuest LLC lifted its stake in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Celldex Therapeutics during the 4th quarter valued at about $121,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.